Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Eherer, AJ; Habermann, W; Hammer, HF; Kiesler, K; Friedrich, G; Krejs, GJ.
Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study.
Scand J Gastroenterol. 2003; 38(5):462-467
Doi: 10.1080/00365520310001860
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Eherer Andreas
- Co-Autor*innen der Med Uni Graz
- Friedrich Gerhard
- Habermann Walter
- Hammer Heinz
- Kiesler Karl
- Krejs Günter Josef
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: The optimal management of patients with reflux-associated laryngitis is unclear. We performed a placebo-controlled crossover trial in patients with proven reflux disease and associated laryngitis to determine the effect of pantoprazole and to gain information on the natural course of the disease. Methods: Sixty-two consecutive non-smoking patients with hoarseness and proven laryngitis were examined. Scores with respect to the larynx and for subjective complaints were determined and 24-h pH-metry to assess acid reflux in the lower oesophagus and pharynx was performed. Patients with pathologic reflux were given the chance to enter a double-blinded randomized crossover trial with pantoprazole 40 mg b.i.d. and placebo for a duration of 3 months each, separated by a 2-week washout period. Results: Twenty-four of 62 patients showed pathological reflux; 21 patients were included in the study and 14 concluded all parts of the study. Both pantoprazole and placebo resulted in a marked improvement in laryngitis scores (decrease of 8.0 +/- 1.4 versus 5.6 +/- 2.6; no significant difference between the 2 treatments) and symptoms after the first 3 months (decrease of oesophageal symptom score of 2.2 +/- 1.4 versus 5.4 +/- 2.8; decrease of laryngeal scores of 8.3 +/- 3.6 versus 10.3 +/- 3.9; also no significant difference between the 2 treatments). A second pH-metry 2 weeks thereafter proved the persistence of reflux in most of these patients. Switching to pantoprazole led to a further improvement of scores. In the group switched to placebo there was recurrence only in a minority of patients. Conclusions: The self-limited nature of reflux-associated laryngitis in non-smokers is largely underestimated. Laryngitis improves despite the persistence of reflux. Pantoprazole may be helpful especially in relieving acute symptoms, but the advantage of long-term treatment over placebo has been greatly overestimated.
- Find related publications in this database (using NLM MeSH Indexing)
- 2-Pyridinylmethylsulfinylbenzimidazoles -
- Adult -
- Aged -
- Anti-Ulcer Agents - therapeutic use
- Benzimidazoles - therapeutic use
- Cross-Over Studies -
- Double-Blind Method -
- Female -
- Gastroesophageal Reflux - complications Gastroesophageal Reflux - drug therapy
- Humans -
- Laryngitis - drug therapy Laryngitis - etiology
- Male -
- Middle Aged -
- Omeprazole - analogs & derivatives
- Proton Pump Inhibitors -
- Recurrence -
- Severity of Illness Index -
- Sulfoxides - therapeutic use
- Find related publications in this database (Keywords)
- gastroesophageal reflux
- GERD
- laryngitis
- reflux-associated laryngitis